Brief: Orchard Therapeutics Announces Global License Agreements For Stable Cell Line Technology From GSK
15/07/2020 12:35
July 15 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS ANNOUNCES GLOBAL LICENSE AGREEMENTS
FOR
STABLE CELL LINE TECHNOLOGY FROM GSK
* ORCHARD THERAPEUTICS PLC - TERMS OF LICENSE ARE NOT
EXPECTED TO
HAVE A MATERIAL IMPACT ON ORCHARD'S FINANCIAL POSITION
* ORCHARD THERAPEUTICS PLC - TERMS OF LICENSE NOT EXPECTED
TO HAVE
A MATERIAL IMPACT ON NEAR-TERM CASH NEEDS
* ORCHARD THERAPEUTICS PLC - PLANS TO SUBMIT BLA AND MAA FOR
OTL-103 FOR TREATMENT OF WAS
Source text for Eikon: ID:nGNX5hc4Jy
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln